Cotargeting VEGF and Neuropilins with Bevacizumab and Secreted Wnt Inhibitors in Prostate Cancer
Abstract
The objectives of this proposal are to test hypotheses: 1) WIF1 IgG fusion protein has an additive or synergistic effect with anti-VEGF therapy to inhibit tumor growth and metastasis; and 2) NRP2 is a wnt target gene and predicts prostate cancer progression. WIF1 IgG fusion protein was produced, but the stability of first fusion protein was poor. Experiments for modification of IgG-WIF1 fusion construct for improving the stability of IgG-WIF1 are in progress. Proposed animal experiments are approved by the UCI IACUC and orthotopic prostate cancer models are established. Chromatin immunoprecipitation (ChIP), luciferase assay, mRNA expression, and bioinformatics analyses demonstrates that NRP2 is a Wnt target gene. NRP2 antibody was validated using tissue array slides.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 18, 2012
- Accession Number
- ADA571470
Entities
People
- Blair Christopher
- Noriko Yokoyama
- Xiaolin Zi
Organizations
- University of California, Irvine